Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Assess the Safety, Tolerability, and Target Engagement of AMX0035, a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimer's Disease

NCT03533257 is registered in ClinicalTrials.gov with Amylyx Pharmaceuticals Inc. as lead sponsor.

NCT NCT03533257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03533257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Assess the Safety, Tolerability, and Target Engagement of AMX0035, a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimer's Disease
Lead sponsor
Amylyx Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 14, 2018
Completion date
November 6, 2020
Enrollment
95 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease